Funding: French retinal implant maker Pixium Vision raises $20M

November 26, 2013 by Arezu Sarvestani

Paris-based Pixium Vision touts a $23.3 million (€15 million) Series A funding round in support of its IRIS retinal implant for treatment of vision-loss due to degenerative eye conditions.

Funding: French retinal implant maker Pixium Vision raises $20M

Retinal implants maker Pixium landed a $20.3 million (€15 million) Series A funding round, planning to use the funds to further develop its IRIS "bionic eye" technology.

The IRIS system is comprised of a retinal implant and a pair of camera-mounted glasses connected to a "pocket computer." The computer processes images captured by the glasses and transmits the data into a signal that's transferred back and projected onto the intraocular implant, where it stimulates the optic nerve and generates images that the brain learns to interpret as visual signals.

Sign up to get our free newsletters delivered right to your inbox.

Pixium in April 2013 launched a clinical trial of the 1st-generation IRIS1 system, expecting initial data next year, which the company will use to support an application for CE Mark approval in the European Union.

The newly raised funds will help complete the clinical trial and develop next-generation IRIS systems, Pixium CEO Dr. Bernard Gilly said in prepared remarks.

Pixium's funding round was led by Sofinnova Partners, now the company's largest investor, with additional funds from Bpifrance, the InnoBio fund and previous investors Omnes Capital and Abingworth LLP. Representatives from Bpifrance and Sofinnova joined Pixium's board in conjunction with the Series A funding, according to a press release.